Core Points - Yong'an Pharmaceutical announced the acquisition of a 49.20% stake in its subsidiary Hubei Ling'an Technology Co., Ltd. for 27 million yuan, aiming to gain 100% ownership of the company [2] Group 1 - The board of directors approved the investment proposal during the ninth temporary meeting of the seventh board session, scheduled for September 24, 2025 [2] - The acquisition will not change the scope of the company's consolidated financial statements [2] - The company has already made the first payment to the sellers as per the share transfer agreement [2] Group 2 - Hubei Ling'an Technology has completed the necessary business registration changes and received a new business license from the market supervision administration [2]

Core Viewpoint - The company plans to acquire 49.20% equity of its subsidiary, Hubei Ling'an Technology Co., Ltd., for 27 million yuan, resulting in 100% ownership after the transaction is completed [1] Group 1 - The acquisition will be funded using the company's own funds [1] - Following the acquisition, the consolidation scope of financial statements will remain unchanged [1] - Hubei Ling'an Technology has completed the necessary business registration changes, with the legal representative changing from Zhang Yong to Chen Yong [1] Group 2 - The company has already paid the first installment of the acquisition price, with subsequent payments to follow [1] - The new business license clarifies the company's basic information and business scope [1] - Investors are reminded to pay attention to risks associated with the transaction [1]

证券代码：002365 证券简称：永安药业 公告编号：2025-59 潜江永安药业股份有限公司 关于子公司湖北凌安科技有限公司完成 二、进展情况 根据《股权转让协议》的约定，公司已向交易对方支付完成第一期价款。近 日，凌安科技已办理完成上述事项相关的工商变更登记手续，并取得了由潜江市 市场监督管理局换发的《营业执照》，具体如下： | 变更事项 | 变更前内容 | 变更后内容 | | --- | --- | --- | | 负责人变更（法定 代表人、负责人、 | 张勇 | 陈勇 | | 首席代表、合伙事 | | | | 务执行人等变更） | | | | 市场主体类型(企 | 其他有限责任公司 | 有限责任公司(自然人投 | | 业类型)变更 | | 资或控股的法人独资) | （1）变更信息如下： | | 股东名称：夏昌培，认缴出资额：113.36 | | | --- | --- | --- | | | 万，币种：人民币，认缴出资方式：货 | | | | 币，认缴出资时间：2018-11-06；股东 | | | | 名称：张勇，认缴出资额：662.62 万， | 股东名称：潜江永安药业 | | 投资人变更（包括 ...

Meeting Overview - The second extraordinary general meeting of shareholders for 2025 was held on October 15, 2025, at 14:30, combining on-site and online voting methods [1][2] - A total of 525 shareholders attended the meeting, representing 77,902,515 shares, which is 26.9424% of the total voting shares [3][4] Voting Results - The proposal to change the business scope, increase the number of board members, and amend the Articles of Association was approved with 99.7578% of the votes in favor, totaling 77,713,815 shares [6][8] - The proposal to amend the governance system was also approved, with 99.7528% of the votes in favor for the amendment of the Shareholders' Meeting Rules [9][11] - The proposal to revise the Board Meeting Rules received 99.7434% approval [12][14] - The proposal to amend the Independent Director Work System was approved with 99.7558% of the votes in favor [15][17] Legal Compliance - The meeting's procedures, including the convening, attendance, and voting, were confirmed to comply with relevant laws and regulations by the witnessing lawyers from Shanghai Jintiancheng (Wuhan) Law Firm [17]

Core Viewpoint - Huanggang Yong'an Pharmaceutical Co., Ltd., a significant shareholder of Qianjiang Yong'an Pharmaceutical Co., Ltd., plans to reduce its shareholding without affecting the company's control [1][2]. Group 1: Shareholding Reduction Announcement - On July 25, 2025, the company disclosed a pre-announcement regarding the planned share reduction by its controlling shareholder, Huanggang Yong'an, who holds 10,529,232 shares (3.5731% of total shares) [1]. - Huanggang Yong'an intends to reduce its holdings by up to 2,632,300 shares (0.8933% of total shares) within three months following the pre-announcement [1]. Group 2: Implementation of Share Reduction - On September 9, 2025, the company reported that Huanggang Yong'an had completed its share reduction plan, having sold 410,000 shares (0.1391% of total shares) on September 4, 2025 [2][3]. - The reduction was executed at a price range of 17.02 to 19.02 yuan per share [2]. Group 3: Compliance and Impact - The share reduction was conducted in compliance with relevant laws and regulations, ensuring no breach of prior commitments [3]. - The reduction will not lead to a change in the company's control or affect its governance structure and ongoing operations [3].

上海市锦天城（武汉）律师事务所 关于潜江永安药业股份有限公司 二○二五年第二次临时股东会的 法律意见书 地址：武汉市江汉区云霞路 187 号民生金融中心 8 层 03-05 电话：027-83828888 邮编：430030 上海市锦天城（武汉）律师事务所 法律意见书 上海市锦天城（武汉）律师事务所 关于潜江永安药业股份有限公司 二○二五年第二次临时股东会的 法律意见书 致：潜江永安药业股份有限公司 上海市锦天城（武汉）律师事务所（以下简称"本所"）接受潜江永安药业 股份有限公司（以下简称"公司"）的委托，委派本律师出席公司二○二五年第 二次临时股东会（下简称"本次股东会"），就公司召开本次股东会的有关事宜， 根据《中华人民共和国公司法》（以下简称《公司法》）《上市公司股东会规则》 等法律、法规、规章和其他规范性文件以及《潜江永安药业股份有限公司章程》 （以下简称《公司章程》）的有关规定，出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚实信用原则，对本次股东会所涉及的相 ...

证券代码：002365 证券简称：永安药业 公告编号：2025-58 潜江永安药业股份有限公司 2025 年第二次临时股东会决议公告 网络投票时间：2025年10月15日 （1）通过深圳证券交易所交易系统进行网络投票的具体时间为：2025年10 月15日上午9:15—9:25,9:30-11:30 和下午13:00—15:00。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决提案的情形； 2、本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、召开时间： 现场会议召开时间：2025年10月15日（星期三）14:30 （2）通过深圳证券交易所互联网投票系统投票的时间为：2025年10月15日 9:15—15:00期间的任意时间。 2、现场会议召开地点：湖北省潜江经济开发区广泽大道2号潜江永安药业股 份有限公司（以下简称"公司"）二楼会议室 3、召开方式：本次股东会采取现场投票和网络投票相结合的方式。 4、股权登记日：2025年10月9日（星期四） 5、召集人：公司董事会； 6、主持人 ...

Core Viewpoint - Yong'an Pharmaceutical experienced a 5.13% increase in stock price, reaching 19.66 CNY per share, with a trading volume of 549 million CNY and a turnover rate of 11.74%, resulting in a total market capitalization of 5.793 billion CNY [1] Company Overview - Yong'an Pharmaceutical Co., Ltd. is located in Qianjiang Economic Development Zone, Hubei Province, and was established on June 18, 2001, with its listing date on March 5, 2010 [1] - The company primarily engages in the research, production, and sales of taurine products, with main business revenue composition being 64.14% from taurine and 35.86% from other products [1] Fund Holdings - According to data, Ping An Fund has a significant holding in Yong'an Pharmaceutical through the Ping An CSI 2000 Enhanced Strategy ETF (159556), which held 3,100 shares in the second quarter, accounting for 0.29% of the fund's net value, ranking as the fourth-largest holding [2] - The Ping An CSI 2000 Enhanced Strategy ETF (159556) was established on December 27, 2023, with a latest scale of 28.7267 million CNY, and has achieved a year-to-date return of 25.42%, ranking 1928 out of 4220 in its category [2] - The fund manager, Yu Yao, has a tenure of 3 years and 347 days, with a total asset scale of 131 million CNY, achieving a best return of 17.23% and a worst return of -20.06% during the tenure [2]

证券代码：002365 证券简称：永安药业 公告编号：2025-57 潜江永安药业股份有限公司 关于公司控股股东、实际控制人之一致行动人 减持计划实施完成的公告 股东黄冈永安药业有限公司保证向本公司提供的信息内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 潜江永安药业股份有限公司（以下简称"公司"、"本公司"）于 2025 年 7 月 25 日披露了《关于公司控股股东、实际控制人之一致行动人拟减持公司股 份的预披露公告》（公告编号：2025-45），公司控股股东、实际控制人之一致 行动人黄冈永安药业有限公司（以下简称"黄冈永安"）持有公司股份 10,529,232 股（占总股本比例 3.5731%，占剔除公司回购专用账户股份后的总股本比例 3.6415%）计划自减持预披露公告披露之日起十五个交易日后的三个月内以集中 竞价交易或大宗交易方式减持公司股份不超过 2,632,300 股（占总股本比例 0.8933%，占剔除公司回购专用账户股份后的总股本比例 0.9104%），本次减持 不会导致公司控制权发生变更。 2025 年 9 月 ...

Core Viewpoint - Yong'an Pharmaceutical's subsidiary, Yong'an Kangjian, has established a dual development model focusing on "contract manufacturing services" and "self-owned brand operations" in the health industry [1] Group 1 - Yong'an Kangjian has been dedicated to the health industry since its inception [1] - The company plans to significantly develop its contract manufacturing services while increasing investment in its self-owned brand business [1] - There will be a focus on enhancing product research and development as well as market promotion to improve market recognition and sustainable development of the self-owned brand business [1]